> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Seattle Genetics Stops Phase 3 Study Due to Deaths
- URL: https://www.fdaweb.com/seattle-genetics-stops-phase-3-study-due-to-deaths/
- Published: 2017-06-19T12:00:00.000Z
- Updated: 2026-09-14T22:30:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138970

Seattle Genetics says it is discontinuing its Phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia patients due to a higher rate of deaths seen in those on the therapy. The company made its decision after consulting with its independent data monitoring committee and after reviewing recent unblinded data. While safety concerns did not appear related to hepatotoxicity, Seattle Genetics said it “is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials including the ongoing phase 1/2 clinical trial in frontline high risk myelodysplastic syndrome.” The company says it will consult with FDA after closely reviewing the data to determine future plans for the drug’s development program.